Chester Davis Jr., Association for Accessible Medicines (AAM) president and CEO, in a recent article took a firm stance against the Trump administration’s recent efforts to cut drug prices.
Davis spotlights the U.S.-Mexico-Canada Agreement (USMCA), a deal which he says “undermines the Trump administration’s own blueprint to lower drug prices.”
“U.S. patients have been forced to forego lifesaving medicines or to stretch a month’s prescription to two by chopping pills in half,” Davis writes. “The President has forcefully pledged to provide relief to these patients and their families, but his own trade policy threatens to undermine this commitment.”